Experimental Study Of The Effects Furongtongmai Capsule Has On The Expression Of Serum Hs-CRP,the Expression Of MCP-1 And ICAM-1 In Thoracic Aorta Tissue Of Diabetic Rats

Objective: By observing the effect Furongtongmai Capsule has on diabetic rats hs-CRP, the MCP-1 and the expression of ICAM-1,which is a Chinese native medicine preparation, invigorating qi, nourishing yin,promoting blood circulationon, to explore its effect in anti inflammation,and then evaluate its effect on diabetes vascular lesions from the aspects of "anti-inflammatory".Methods: We selected 70 adult male Wistar rats whose weights were from 190 g to 230 g,then,randomly divided them into two groups at random,normal control group(12 rats)(NC, n = 12)and diabetic model groups(58 rats).12 hours after fasting,streptozocin(STZ), 60 mg/kg(mix STZ with 0.1 M sodium citrate buffer solution to 1%, p H= 4.2) was injected into the abdominal cavity in one time to creat the making model group rats.After we injected the same amount of sodium citrate buffer into abdominal cavity of the Normal control group rats. After 72 hours,took blood from caudal vein to measure blood glycemia. Rats whose glycemia≥16.7mmol/L were defined as diabetic rats. Building a total of 51 diabetes rats successfully.And then,we randomly divided 48 diabetic rats into four groups at random,diabetic model control group( DM, n=12) low-dose Furongtongmai Capsule treated group[FL,0.7g/(kg?d)](n = 12)middle-dose treated group[FM,1.4g/(kg?d)](n =12)、and high-dose treated group[FH,2.8g/(kg?d)](n = 12).We lavaged the rats of FL 、FM 、FH groups with low-dose、middle-dose and high-dose Furongtongmai Capsul daily for 8 weeks.At the same time,we fed rats of the other two groups with equal volume of physiological saline. During experiment period,each group of rats were allowed to drink, and eat standard feed,the temperature of the environment is 22 to 26 degrees.After 8 weeks, allrats were tabken blood from tail vein,used to measure blood glycemia after fasting 12 hours,and then collected abdominal aortic blood in all rats after anesthetized by intraperitoneal injecting 3% pentobarbital sodium(80mg/kg) to test Serum triglyceride(TG)cholesterol(TC) and hs- CRP. Then,we rinsed2.0cm thoracic aorta from all rats and kept them in physiological saline to remove blood, and fixed them in 4% Paraformaldehyde.At last,we used immunoshistochemistry assay to detect MCP-1 and ICAM-1.All quantitative date were expressed in ? X±S. Useing One-way ANOVA in comparison among groupsand,and useing T test in comparison of before and after treatment. Observations were accomplished by SPSS 16.0. When P < 0.05,there are significant statistical significance.Results:1 The change of blood glucoseBefore treatment,diabetes group、low-dose、middle-dose and high-dose Furongtongmai Capsule treated groups compared with the normal control group,the blood glucose were significantly higher(P<0.05);Among diabetes group、low-dose 、middle-dose and high-dose Furongtongmai Capsule treated groups,there was no obviously difference(P>0.05).After 8 weeks treatment,the blood glucose of each group had no obviously difference before and after treatment(P>0.05);Among diabetes group、low-dose、middle-dose and high-dose Furongtongmai Capsule treated groups,there was no obviously difference(P>0.05).2 The change of weightBefore treatment, the weight of rats had no obviously difference(P>0.05).After 8 weeks treatment, the weights of the normal control group were significantly increaed comparied with before treatment(P<0.05);The weights of diabetes group 、low-dose、middle-dose and high-dose Furongtongmai Capsule treated groups were significantly decreased comparied with before treatment(P<0.05); The weight of rats of diabetes group 、 low-dose 、middle-dose and high-dose Furongtongmai Capsule treated groups were significantly lower than that of the normal control group(P<0.05); Amongdiabetes group 、 low-dose 、 middle-dose and high-dose Furongtongmai Capsule treated groups,there was no obviously difference(P>0.05).3 The change of lipid8 weeks after treatment, compared with the control group,diabetes group、low-dose、middle-dose and high-dose Furongtongmai Capsule treated groups,the levels of TG were obviously higher(P<0.05); the levels of TC had no obviously difference(P>0.05); The low-dose 、 middle-dose and high-dose Furongtongmai Capsule therapy group compared with diabetes group, the levels of TG、TC were not obviously different(P>0.05);the levels of TG、TC were not obviously different among the low-dose 、 middle-dose and high-dose Furongtongmai Capsule treated groups(P>0.05).4 The expression of serum hs-CRP8 weeks after treatment, diabetes group and Furongtongmai Capsule low-dose group, compared with the normal control group,serum hs- CRP levels were obviously higher(P< 0.05); Normal control group,compared the middle-dose and high-dose Furongtongmai capsule group, there was no obvious difference(P>0.05).Furongtongmai capsule low dose group compared with diabetes group, serum hs-CRP levels were not obviously changed(P>0.05); Furongtongmai capsule middle-dose and high-dose group,compared with the diabetic group, serum hs-CRP levels decreased significantly(P< 0.05); Furongtongmai capsule middle-dose and high-dose groups compared with Furongtongmai capsule low-dose group,serum hs-CRP levels were significantly decreased(P< 0.05);Furongtongmai capsule middle-dose group compared with high-dose group, serum hs-CRP levels were not significantly changed(P>0.05);5 The expression of the MCP-1 in thoracic aorta tissue8 weeks after treatment, compared with the diabetic group and Furongtongmai capsule low dose group, the expression of MCP-1 in the control group thoracic aorta were significantly lower(P<0.05); Normal control group,compared the middle-dose and high-dose Furongtongmai capsule groups, there was no obvious difference(P>0.05);Furongtongmaicapsule low dose group compared with diabetes group, the expression of the MCP-1 had no obvious difference(P>0.05); Furongtongmai capsule middle-dose and high-dose group compared with diabetes group, the expression of the MCP-1 significantly decreased(P< 0.05); Furongtongmai capsule middle-dose and high-dose groups compared with the Furongtongmai capsule low-dose group, the expression of the MCP-1 significantly decreased(P< 0.05);Furongtongmai capsule middle-dose group compared with high-dose group, the level of serum MCP-1 were not significantly changed(P>0.05);6 The expression of ICAM-1 in thoracic aorta tissue8 weeks after treatment, compared with the diabetic group and Furongtongmai capsule low dose group, the expression of ICAM-1 in the control group thoracic aorta were significantly lower(P<0.05);Normal control group,compared the middle-dose and high-dose Furongtongmai capsule group,there was no significant difference(P> 0.05); Furongtongmai capsule low dose group compared with diabetes group, the expression of the ICAM-1 had no obvious difference(P> 0.05); Furongtongmai capsule middle-dose and high dose group compared with diabetes group, the expression of the ICAM-1significantly decreased(P< 0.05);Furongtongmai capsule middle-dose and high dose group compared with the Furongtongmai apsule low-dose group, the expression of the ICAM-1 significantly decreased(P< 0.05);Furongtongmai capsule middle-dose group compared with high-dose group, the level of serum ICAM-1 were not significantly changed(P>0.05);Conclusion:1 Furongtongmai Capsule has no obvious hypoglycemic, lipid-lowering effect.2 Furongtongmai Capsule has no obvious effect on the weight of diabetic rats.3 It was suggested that Furongtongmai Capsule can significantly inhibit the serum hs-CRP levels of the diabetic rats.4 Furongtongmai Capsule can significantly inhibit the expression ofICAM 1 and MCP-1 in aortic endothelium in diabetic rat’s abdomen.5 In the aspect of inhibiting the inflammation, Furongtongmai Capsule can protect the vascular endothelium.Middle dose is enough when we treat diabetes vascular lesions.